Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Genentech granted FDA hearing on Avastin for metastatic breast cancer

Genentech, a member of the Roche Group, today announced the U.S. Food and Drug Administration (FDA) has granted a hearing to allow the company the opportunity to present its views on why Avastin® (bevacizumab) should remain FDA-approved for metastatic breast cancer (mBC). The FDA has scheduled the hearing for June 28 to 29, 2011.

25 Feb 2011

Transgenic fungal approach can fight against malaria and bug-borne diseases

New findings by a University of Maryland-led team of scientists indicate that a genetically engineered fungus carrying genes for a human anti-malarial antibody or a scorpion anti-malarial toxin could be a highly effective, specific and environmentally friendly tool for combating malaria, at a time when the effectiveness of current pesticides against malaria mosquitoes is declining.

24 Feb 2011

FDA approves sBLA for CSL's Hizentra to treat PI

CSL Behring announced today that the U.S. Food and Drug Administration has approved a supplemental Biologics License Application to extend the shelf life of Hizentra, Immune Globulin Subcutaneous, 20% Liquid, from 24 months to 30 months.

24 Feb 2011

Steroid administration may impact immune system in children with asthma

Children experiencing an asthma attack who are treated with a short burst of oral steroids may have a transient depression of immune response according to a new study led by Universit- de Montr-al.

24 Feb 2011

CST, Astellas Pharma enter commercialization partnership for cancer diagnostic, therapeutic products

Cell Signaling Technology, Inc. of Danvers, MA announced today a joint commercialization partnership with Astellas Pharma, Inc. of Tokyo, Japan focused on the delivery of personalized cancer therapeutics and diagnostics.

From Cell Signaling Technology 24 Feb 2011

Study results of NanoViricides anti-dengue drug candidates presented at NIH/NIAID sponsored conference

NanoViricides, Inc.announced today that Anil R. Diwan, PhD, President of the Company, gave a presentation on Friday, February 18th, that discussed the Company's anti-viral technology and more specifically, results from both in-vitro and in-vivo studies of its drug candidates against dengue virus infections that can potentially cause a fatal manifestation, viz. dengue hemorrhagic fever.

23 Feb 2011

Intercell places EUR 33.0m of Senior Unsecured Convertible Notes in private placement transaction

Intercell AG today announced that it successfully placed EUR 33.0m of Senior Unsecured Convertible Notes in a private placement transaction, which was increased due to investor demand.

23 Feb 2011

Biochemist receives STAC grant to find treatment for C. albicans infection in premature infants

A $200,000 grant from the Rhode Island Science and Technology Advisory Council is helping a Bryant University biochemist find a treatment for a fungal infection that is often lethal to premature infants.

23 Feb 2011

New nanoparticle can help develop vaccines against HIV, malaria

MIT engineers have designed a new type of nanoparticle that could safely and effectively deliver vaccines for diseases such as HIV and malaria.

23 Feb 2011

Study: Antibody-directed chemotherapy may be effective for majority of younger AML sufferers

Antibody-directed chemotherapy offers improved survival to particular sub-groups of leukaemia sufferers, a Cardiff University-led study has found.

23 Feb 2011

Why are Chlamydia and HPV major public health problems?

Chlamydia trachomatis is a bacterium that is one of the most common sexually transmitted infections in Europe. Rates in sexually active young people are commonly between 5% and 10%. The number of diagnosed cases is increasing in many European countries, in part due to increased testing and the use of more sensitive tests.

22 Feb 2011

FDA approves OraSure's rapid antibody test to detect HCV

OraSure Technologies, Inc. announced today that its OraQuick HCV Rapid Antibody Test has now been approved by the U.S. Food and Drug Administration for use in detecting HCV antibodies with a fingerstick whole blood sample.

22 Feb 2011

Pharming, Santarus begin RHUCIN Phase IIIb study in patients with Hereditary Angioedema

Specialty biopharmaceutical company Santarus, Inc. and biotech company Pharming Group NV (NYSE Euronext: PHARM) today announced that Pharming has begun an international, multicenter, randomized, placebo-controlled Phase IIIb clinical study evaluating the investigational drug RHUCIN for the treatment of acute attacks of angioedema in patients with Hereditary Angioedema.

22 Feb 2011

MorphoSys completes technology transfer in strategic antibody alliance

MorphoSys AG (FSE: MOR; Prime Standard Segment) announced today that it has received a technology milestone payment from Novartis in connection with completion of the installation of its HuCAL antibody platform at Novartis Institutes for BioMedical Research in Basel, Switzerland.

22 Feb 2011

Life Technologies announces winners of European Ion Torrent PGM Sequencer Grants Program

Life Technologies Corporation, today announced Dr. Angel Carracedo and Dr. Mark Pallen as the winners of the European Ion Torrent Personal Genome Machine (PGM™) Sequencer Grants Program.

19 Feb 2011

Biocare, HJF sign license agreement to distribute antibody against prostate cancer

The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. has signed a licensing agreement with Biocare Medical, a biotechnology company based in Concord, Calif., for the exclusive worldwide sales and distribution rights for the immunohistochemistry of an antibody designed to detect tumor prevalence in prostate cancer patients.

18 Feb 2011

USPTO issues two patents to VIRxSYS SMaRT RNA platform technology

VIRxSYS Corporation, a privately-held biotechnology company with proprietary RNA payload and lentiviral vector delivery platform technologies, today announced that the United States Patent and Trademark Office has issued the Company two patents for its SMaRT RNA platform technology, capable of reprogramming or repairing genes to create, increase or change protein expression.

18 Feb 2011

Antibody News and Research

Further Reading

Genentech granted FDA hearing on Avastin for metastatic breast cancer

Transgenic fungal approach can fight against malaria and bug-borne diseases

FDA approves sBLA for CSL's Hizentra to treat PI

Steroid administration may impact immune system in children with asthma

CST, Astellas Pharma enter commercialization partnership for cancer diagnostic, therapeutic products

Study results of NanoViricides anti-dengue drug candidates presented at NIH/NIAID sponsored conference

Intercell places EUR 33.0m of Senior Unsecured Convertible Notes in private placement transaction

Biochemist receives STAC grant to find treatment for C. albicans infection in premature infants

New nanoparticle can help develop vaccines against HIV, malaria

Study: Antibody-directed chemotherapy may be effective for majority of younger AML sufferers

Why are Chlamydia and HPV major public health problems?

FDA approves OraSure's rapid antibody test to detect HCV

Pharming, Santarus begin RHUCIN Phase IIIb study in patients with Hereditary Angioedema

MorphoSys completes technology transfer in strategic antibody alliance

Life Technologies announces winners of European Ion Torrent PGM Sequencer Grants Program

Biocare, HJF sign license agreement to distribute antibody against prostate cancer

USPTO issues two patents to VIRxSYS SMaRT RNA platform technology

World's first cancer stem cell-targeting chemical missile

Positive preliminary data from ongoing PSMA ADC phase 1 study against prostate cancer

Acorda reports fourth quarter net revenue of $133.1 million for full year ended December 31, 2010

Monoclonal Antibody Manufacturing Trends eBook eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News